Početna › Difuzni veliki B-stanični limfom › Maryland
Kliničke studije za Difuzni veliki B-stanični limfom u državi Maryland
13 studija za Difuzni veliki B-stanični limfom traži sudionike na lokacijama u državi Maryland.
Gradovi u državi Maryland
Službeni tekst studije (engleski)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
- The Center for Cancer and Blood Disorders, Bethesda
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT06500273Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Walter Reed National Military Medical Center, Bethesda
- National Institutes of Health Clinical Center, Bethesda
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT06649812A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- American Oncology Partners of Maryland Pa, Bethesda
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT05006716Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- National Institutes of Health Clinical Center, Bethesda
U tijeku regrutacijaFaza 1/2
Od 18 do 120 godina · Oba spola · Ažurirano 28. ruj 2026. · NCT03223610A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- American Oncology Partners, P.A. ( Site 0185), Bethesda
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06717347A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06091865Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- National Institutes of Health Clinical Center, Bethesda
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 16. ruj 2026. · NCT04002947Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
- National Institutes of Health Clinical Center, Bethesda
U tijeku regrutacijaFaza 1
Od 18 do 120 godina · Oba spola · Ažurirano 25. kol 2026. · NCT05389423Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 5. kol 2026. · NCT06116110DALY II USA/ MB-CART2019.1 for DLBCL
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 13. srp 2026. · NCT04792489A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- National Institute of Health, Bethesda
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 2. srp 2026. · NCT05131022A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- National Institutes of Health Clinical Center, Bethesda
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 20. ožu 2026. · NCT04830137Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 2. velj 2026. · NCT05633615Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.